24
Participants
Start Date
December 31, 2011
Primary Completion Date
March 31, 2015
Study Completion Date
March 31, 2015
Everolimus
Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
Pasireotide
Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
Comprehensive Cancer Center of Wake Forest University, Winston-Salem
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill
Moffitt Cancer Center, Tampa
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
UNC Lineberger Comprehensive Cancer Center
OTHER